Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 55Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Advanced Breast Cancer 4Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Solid Malignancies 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Pancreatic Neoplasms 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1

Interventions

Carboplatin 40Paclitaxel 30Bevacizumab 16Gemcitabine 14Cyclophosphamide 14liposomal doxorubicin 13Taxes 12Topotecan 11Cisplatin 11Docetaxel 7veliparib 6pembrolizumab 6olaparib 6Doxorubicin 6Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5sargramostim 4fludarabine 4aldesleukin 4Specimen Handling 4Oxaliplatin 4Leucovorin 4Immunoglobulin G 4Filgrastim 4Drug Therapy 4Disulfides 4Biopsy 4talazoparib 3mirvetuximab soravtansine 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Fallopian Tube Neoplasms × Fulvestrant × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡